Is Journavx indicated for migraine treatment?

Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term (acute) moderate to severe pain. Journavx is a sodium channel blocker that relieves pain by blocking pain-sensing nerves around the body from transmitting pain messages to the spinal cord and brain. Since it does not affect the brain, is expected to have no addictive potential, unlike other pain treatments such as opioids.

Journavx's mechanism of action is by selectively blocking NaV1.8, a sodium channel on pain-sensing nerve cells (neurons), this inhibits pain signals going to the spinal cord and brain.

Journavx (suzetrigine) tablets are taken twice daily, every 12 hours after the first dose.

Journavx FDA approval was received on January 30, 2025, for treating moderate to severe acute pain in adults. This approval was based on positive results from Phase 3 clinical trials (VX21-548-101 and VX21-548-102), which showed that it effectively reduced acute pain for 48 hours after surgery.

Source and more information: https://www.drugs.com/journavx.html

Regards, masso